Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

A Randomized Pilot Study of Online Hatha Yoga for Physical and Psychological Symptoms Among Survivors of Allogenic Bone Marrow Transplant
Eckert, Ryan , Huberty, Jennifer , Kurka, Jonathan , Palmer, Jeanne , Huberty, Jennifer , Laird, Breanne , Mesa, Ruben A.

Mayo Clinic

International Journal of Yoga Therapy | October 28, 2022 | Volume: 32 | Issue: 2022 | Pages: No page available

10.17761/2022-d-21-00047 | PMID 36305845 Get It

Abstract Bone marrow transplant (BMT) is a curative procedure for patients with hematological malignancies, hemoglobinopathies, and errors of inborn metabolism. Survivors are not without symptom burden. The purpose of this study was to assess the feasibility of a 12-week online yoga intervention compared to an educational control group in survivors of allogenic BMT. Participants were recruited nationally. Consenting participants were assigned to online yoga or a podcast control. Yoga and control group participants were instructed to complete 12 weeks of 60 minutes/week of online yoga and podcasts, respectively. Study participants were asked to complete online questionnaires at baseline (wk 0), midpoint (wk 6), postintervention (wk 12), and follow-up (wk 20). Feasibility benchmarks included > 70% satisfied with intervention and > 70% intending to continue participating in online yoga (acceptability); > 70% of participants achieving > 42 minutes/week of online yoga (demand); > 70% completing all four questionnaires (practicality); and at least small effect sizes of the intervention on Lee Symptom Score, physical function, fatigue, anxiety, sleep disturbance, social functioning, pain interference, depression, and quality of life as compared to control group (limited efficacy). Seventy-two participants consented and enrolled in the study (yoga group n = 33; podcast group n = 39). Of the yoga group participants, 54.5% (n = 19) completed the postintervention questionnaire, with 73.7% (n = 14) indicating they were satisfied/very satisfied and 15.8% (n = 3) likely/very likely to continue online yoga. Yoga participation averaged 31.98 minutes/week across 12 weeks. Both groups experienced a significant improvement in the Lee Symptom Score (6.2%–8.7% improvement from baseline) and depressive symptoms (5.3%–6.6% improvement from baseline). The yoga group experienced a significant reduction in pain (6.1% from baseline), and the podcast group experienced a significant reduction in fatigue (6.4% improvement from baseline). Online yoga was not found to be feasible to deliver to this population of survivors of BMT. However, there was satisfaction with online yoga among the majority of survivors of BMT, and beneficial effects were experienced in the yoga group on Lee Symptom Score, depressive symptoms, and pain. Future research is needed to enhance our understanding of barriers to online yoga participation for survivors of BMT and to determine its efficacy.
Response Rates of Invasive Lobular Cancer in Patients Undergoing Neoadjuvant Endocrine or Chemotherapy
Jakub, James W. , Zhang, Wenexia , Solanki, Malvika , Harmsen, Scott, Zhang, Wenxia , Yonkus, Jennifer, Jakub, James W , Yonkus, Jennifer A. , Boughey, Judy C. , Giridhar, Karthik V.

Mayo Clinic

The American Surgeon™ | October 28, 2022 | Volume: 89 | Issue: 2 | Pages: 230-237

10.1177/00031348221135778 | PMID 36305029 Get It

Background A gap remains in the role of neoadjuvant therapy for patients with ILC. Method Single-institution retrospective review of patients with ILC who received neoadjuvant therapy between 2008 and 2019. Results 141 patients met inclusion criteria: 71 neoadjuvant chemotherapy (NACT) and 70 neoadjuvant endocrine therapy (NET). 7/71 (9.9%) patients had a pCR following NACT compared to 1/70 (1.4%) with NET ( P = .063). pCR was observed in 5/18 (27.8%) patients with Her2Neu-positive disease following NACT, compared to 2/53 (3.8%) with Her2Neu-negative disease ( P = .01). For luminal B tumors, median Ki-67 decrease was similar following NACT and NET (18.3 vs 16.3, P = .26). T category decreased in 59 (42.1%) patients following neoadjuvant therapy, increased in 9 (6.4%), and was unchanged in 72 (51.4%). More patients had an increase (28.6%) than decrease (12.1%) in their N category, including 13/60 (21.7%) who were clinically node-negative at diagnosis and identified to have node-positive disease following neoadjuvant therapy, at definitive surgery. Conclusion In Her2Neu-negative ILC, the potential of a pCR with NACT or NET is low. Most patients’ nodal status and tumor size remain unchanged. There is a potential for pathologic stage to be higher at surgery compared to the clinical stage prior to neoadjuvant therapy.
Characteristics and Perspectives of Human Trafficking Education: A Survey of U.S. Medical School Administrators and Students
Talbott, Jennifer , Lee, Yeonsoo Sara , Titchen, Kanani , Chen, Joyce Y., Kling, Juliana M. , Talbott, Jennifer M V , Sara Lee, Yeonsoo , Kling, Juliana M

Mayo Clinic

Journal of Women's Health | October 27, 2022 | Volume: 32 | Issue: 2 | Pages: 192-198

10.1089/jwh.2022.0144 | PMID 36301184 Get It

Objective: To assess the timing, duration, methodology, and content of human trafficking (HT) curricula in U.S. medical schools. Methods: An anonymous, cross-sectional survey was sent through email and phone to administrators of 199 U.S. allopathic and osteopathic medical schools. A supplementary survey was sent to students and faculty through email listservs and social media links. Data collection occurred from April to October 2020 and findings were analyzed through SAS software. All study measures were approved by the institutional review board. Results: Administrators were from 22 states and 34 schools ( n = 51/199 schools; response rate: 25.6%) and n = 41 responded to all questions. Of these, 32% (13/41) self-identified as deans, 34.1% (14/41) as faculty, and 29.3% (12/41) as other administrators. Less than half (41.5%, n = 17/41) reported an HT curriculum. There was a wide range in length (average = 3 hours) and when present was almost always mandatory ( n = 51, 88.2%). Few curricula mentioned labor (23.5%) or organ (5.9%) trafficking, or at-risk populations such as lesbian, gay, bisexual, trans, queer, and intersex (LGBTQI) members (13.7%), foreign nationals (7.8%), victims of political conflict (3.9%), and indigenous peoples (2.0%). Students and staff ( n = 242) were from 34 states and 83 schools, and n = 36 (27.5%) reported a curriculum. Less than half (44.4%) felt the length (average 4.1 hours) was sufficient. Conclusions: Less than half of respondents reported an HT curriculum. It is unclear how well this curriculum prepares students to treat victim-survivors of HT. Future work is necessary to incorporate effective education on HT for trainees and evaluate patient outcomes after curricular implementation.
Narrative review of peripheral nerve blocks for the management of headache
Stern, Jennifer I. , Chiang, Chia‐Chun , Robertson, Carrie E. , Chiang, Chia-Chun , Robertson, Carrie E , Kissoon, Narayan

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 26, 2022 | Volume: 62 | Issue: 9 | Pages: 1077-1092

10.1111/head.14385 | PMID 36286600 Get It

Abstract Objective To provide an overview of the current available literature on peripheral nerve blocks for the management of migraine and other headache disorders in adults. Background Peripheral nerve blocks have been commonly performed in the headache practice for migraine, cluster headache, occipital neuralgia, and other headache disorders, despite a paucity of evidence supporting their use historically. In the past decade, there has been an effort to explore the efficacy and safety of peripheral nerve blocks for the management of headache, with the greatest interest centered around greater occipital blocks. Design We performed a search in PubMed using key words including “occipital nerve blocks,” “peripheral nerve blocks,” “occipital nerve,” “migraine,” “cluster headache,” and “neuralgia.” We reviewed the randomized controlled trials (RCTs), observational studies, and case series, and summarized the anatomy, techniques, and the evidence for the use of peripheral nerve blocks in different headache disorders, with particular focus on available RCTs. Case reports were included for a detail review of adverse events. Results Of 12 RCTs examining the use of greater occipital nerve blocks for migraine, all but one demonstrate efficacy with reduction in headache frequency, intensity, and/or duration compared to placebo. Studies have not demonstrated a difference in clinical outcomes with the use of corticosteroids for nerve blocks compared to blocks with local anesthetic in the treatment of migraine. There are two RCTs supporting the use of greater occipital blockade for cluster headache, both showing benefit of suboccipitally injected corticosteroid. One RCT suggests benefit of greater occipital nerve blocks for cervicogenic headache. Observational studies and case series/reports show that greater occipital nerve block may be effective in prolonged migraine aura, status migrainosus, post‐dural puncture headache, and occipital neuralgia. Overall, peripheral nerve blocks are well tolerated. Serious side effects are rare but have been reported, including acute cerebellar syndrome and infection. Conclusions Peripheral nerve blocks, especially occipital nerve blocks, are a viable treatment option for migraine and may be helpful in cluster headache as a transitional therapy or rescue therapy. Additional prospective studies are needed to investigate the efficacy and safety of occipital nerve blocks for long‐term migraine prevention, as well as for other headache disorders, such as occipital neuralgia.
Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
Storandt, Michael H. , Gile, Jennifer , Palmer, Mathias Earl, Ahn, Daniel H. , Bekaii‐Saab, Tanios , Jin, Zhaohui , Tran, Nguyen H. , Mahipal, Amit , Gile, Jennifer Jane , Palmer, Mathias E, Zemla, Tyler J, Jin, Zhaohui , Tran, Nguyen , Mahipal, Amit , Bekaii-Saab, Tanios S , Zemla, Tyler

Mayo Clinic

Cancers | October 23, 2022 | Volume: 14 | Issue: 21 | Pages: 5173

10.3390/cancers14215173 | PMID 36358592 Get It

(1) Background: Cabozantinib, a multikinase inhibitor, is approved by the Food and Drug Administration (FDA) for the treatment of advanced hepatocellular carcinoma (HCC) following progression on sorafenib. Recently, atezolizumab plus bevacizumab has been approved in the first line setting for advanced HCC and has become the new standard of care. Whether cabozantinib improves outcomes following progression on immunotherapy remains unknown. We describe the clinical outcomes following treatment with immunotherapy in patients with advanced HCC who received cabozantinib. (2) Methods: We conducted a multicentric, retrospective analysis of patients with advanced HCC diagnosed between 2010–2021 at Mayo Clinic in Minnesota, Arizona, and Florida who received cabozantinib. Median overall survival and progression free survival analyses were performed using the Kaplan–Meier method. Adverse events were determined using Common Terminology Criteria for Adverse Events (CTCAE). (3). Results: We identified 26 patients with advanced HCC who received cabozantinib following progression on immunotherapy. Median progression free survival on cabozantinib therapy was 2.1 months (95% CI: 1.3–3.9) and median overall survival from time of cabozantinib initiation was 7.7 months (95% CI: 5.3–14.9). (4) Conclusion: The optimal sequencing of therapy for patients with advanced HCC following progression on immunotherapy remains unknown. Our study demonstrates that patients may benefit from treatment with cabozantinib following progression on immunotherapy.
Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation
Scott, Frank I. , Ehrlich, Orna , Wood, Dallas , Viator, Catherine, Rains, Carrie, DiMartino, Lisa , McArdle, J. Ardle , Barkoff, Lara, Caudle, Jennifer, Cheng, Jianfeng, Kinnucan, Jami , Persley, Kimberly M., Sariego, Jennifer, Shah, Samir A. , Heller, Caren, Rubin, David T , Scott, Frank I , Rains, Caroline B. , Adams, Gabrielle, Rubin, David T.

Mayo Clinic

Inflammatory Bowel Diseases | October 22, 2022 | Volume: 29 | Issue: 8 | Pages: 1177-1190

10.1093/ibd/izac216 | PMID 36271884 Get It

Abstract Background Recommendations regarding signs and symptoms that should prompt referral of patients with inflammatory bowel disease (IBD) to an IBD specialist for a consultation could serve to improve the quality of care for these patients. Our aim was to develop a consult care pathway consisting of clinical features related to IBD that should prompt appropriate consultation. Methods A scoping literature review was performed to identify clinical features that should prompt consultation with an IBD specialist. A panel of 11 experts was convened over 4 meetings to develop a consult care pathway using the RAND/UCLA Appropriateness Method. Items identified via scoping review were ranked and were divided into major and minor criteria. Additionally, a literature and panel review was conducted assessing potential barriers and facilitators to implementing the consult care pathway. Results Of 43 features assessed, 13 were included in the care pathway as major criteria and 15 were included as minor criteria. Experts agreed that stratification into major criteria and minor criteria was appropriate and that 1 major or 2 or more minor criteria should be required to consider consultation. The greatest barrier to implementation was considered to be organizational resource allocation, while endorsements by national gastroenterology and general medicine societies were considered to be the strongest facilitator. Conclusions This novel referral care pathway identifies key criteria that could be used to triage patients with IBD who would benefit from IBD specialist consultation. Future research will be required to validate these findings and assess the impact of implementing this pathway in routine IBD-related care.
Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer
Oswalt, Cameron , Liu, Yingzhou , Pang, Herbert , Wang, Xiaofei , Crawford, Jeffrey , Crawford, Jeffrey , Liu, Yingzhou, Le‐Rademacher, Jennifer

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | October 21, 2022 | Volume: 13 | Issue: 6 | Pages: 2650-2660

10.1002/jcsm.13095 | PMID 36268548 Get It

AbstractBackgroundWeight loss (WL) has been associated with shorter survival in patients with advanced cancer, while obesity has been associated with longer survival. Integrating body mass index (BMI) and WL provides a powerful prognostic tool but has not been well‐studied in lung cancer patients, particularly in the setting of clinical trials.MethodsWe analysed patient data (n = 10 128) from 63 National Cancer Institute sponsored advanced non‐small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) trials. Risk matrices were created using BMI and WL percentage, which were divided into ‘grades’ based on median survival. Relationships between survival, BMI and WL percentage were examined using Kaplan–Meier estimators and Cox proportional hazards (PH) models with restricted cubic splines.ResultsFor NSCLC, a twofold difference was noted in median survival between the BMI > 28 and WL ≤ 5% group (13.5 months) compared with the BMI < 20 and WL > 5% group (6.6 months). These associations were less pronounced in SCLC. Kaplan–Meier curves showed significant survival differences between grades for both NSCLC and SCLC (log‐rank, P < 0.0001). In Stage IV NSCLC, Cox PH analyses with restricted cubic splines demonstrated significant associations between BMI and survival in both WL ≤ 5% (P = 0.0004) and >5% (P = 0.0129) groups, as well as in WL > 5% in Stage III (P = 0.0306). In SCLC, these relationships were more complex.ConclusionsBMI and WL have strong associations with overall survival in patients with advanced lung cancer, with a greater impact seen in NSCLC compared with SCLC. The integration of a BMI/WL grading scale may provide additional prognostic information and should be included in the evaluation of therapeutic interventions in future clinical trials in advanced lung cancer.
Hepatology highlights
Tomlinson, Jennifer L. , Ramkissoon, Resham­ , Tomlinson, Jennifer , Penrice, Daniel D. , Udompap, Prowpanga , Arab, Juan Pablo

Mayo Clinic

Hepatology | October 19, 2022 | Volume: 76 | Issue: 5 | Pages: 1231-1232

10.1002/hep.32747 Get It

The many faces of globular glial tauopathy: A clinical and imaging study
Buciuc, Marina , Koga, Shunsuke , Pham, Nha Trang Thu, Ali, Farwa , Graff‐Radford, Jon, Lowe, Val J. , Nguyen, Aivi T. , Reichard, Ross R., Petersen, Ronald C. , Whitwell, Jennifer L. , Josephs, Keith A. , Whitwell, Jennifer , Josephs, Keith A , Koga, Shunsuke , Buciuc, Marina , Nguyen, Aivi T , Duffy, Joseph R. , Knopman, David S. , Boeve, Bradley F. , Graff‐Radford, Jonathan , Botha, Hugo , Dickson, Dennis W.

Mayo Clinic

European Journal of Neurology | October 18, 2022 | Volume: 30 | Issue: 2 | Pages: 321-333

10.1111/ene.15603 | PMID 36256511 Get It

AbstractBackgroundGlobular glial tauopathy (GGT) has been associated with frontotemporal dementia syndromes; little is known about the clinical and imaging characteristics of GGT and how they differ from other non‐globular glial 4‐repeat tauopathies (N4GT) such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD).MethodsFor this case–control study the Mayo Clinic brain banks were queried for all cases with an autopsy‐confirmed diagnosis of GGT between 1 January 2011 and 31 October 2021. Fifty patients with N4GT (30 PSP, 20 CBD) were prospectively recruited and followed by the Neurodegenerative Research Group at Mayo Clinic, Minnesota. Magnetic resonance imaging was used to characterize patterns of gray/white matter atrophy, MR‐parkinsonism index, midbrain volume, and white matter hyperintensities.18F‐Fluorodeoxyglucose‐, 11C Pittsburg compound‐, and 18F‐flortaucipir‐positron emission tomography scans were reviewed.ResultsTwelve patients with GGT were identified: 83% were women compared to 42% in NG4T (p = 0.02) with median age at death 76.5 years (range: 55–87). The most frequent clinical features were eye movement abnormalities, parkinsonism, behavioral changes followed by pyramidal tract signs and motor speech abnormalities. Lower motor neuron involvement was present in 17% and distinguished GGT from NG4T (p = 0.035). Primary progressive apraxia of speech was the most frequent initial diagnosis (25%); 50% had a Parkinson‐plus syndrome before death. Most GGT patients had asymmetric frontotemporal atrophy with matching hypometabolism. GGT patients had more gray matter atrophy in temporal lobes, normal MR‐parkinsonism index, and larger midbrain volumes.ConclusionsFemale sex, lower motor neuron involvement in the context of a frontotemporal dementia syndrome, and asymmetric brain atrophy with preserved midbrain might be suggestive of underlying GGT.
Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients
Lehrer, Eric J. , Gurewitz, Jason , Bernstein, Kenneth , Fakhoury, Kareem , Rusthoven, Chad G. , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Malouff, Timothy D. , Peterson, Jennifer , Bonney, Phillip A. , Hwang, Lindsay , Yu, Cheng , Zada, Gabriel , Deibert, Christopher P., Prasad, Rahul N. , Raval, Raju R. , Patel, Samir , Franzini, Andrea , Attuati, Luca , Mathieu, David , Trudel, Claire, Lee, Cheng-chia, Green, Sheryl , Ahluwalia, Manmeet S. , Sheehan, Jason P. , Peterson, Jennifer L., Mathieu, David , Ahluwalia, Manmeet S , Kondziolka, Douglas , Ruiz-García, Henry , Palmer, Joshua D. , Picozzi, Piero , Yang, Huai‐Che , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | October 18, 2022 | Volume: 91 | Issue: 6 | Pages: 872-882

10.1227/neu.0000000000002127 | PMID 36255215 Get It

BACKGROUND: Melanoma brain metastases are commonly treated with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs). However, the toxicity of these 2 treatments is largely unknown when administered concurrently. OBJECTIVE: To evaluate the risk of radiation necrosis (RN) with concurrent and nonconcurrent SRS and ICIs. METHODS: The guidelines from the Strengthening the Reporting of Observational Studies in Epidemiology checklist were used. Inverse probability of treatment weighting, univariable and multivariable logistic regression, and the Kaplan-Meier method was utilized. RESULTS: There were 203 patients with 1388 brain metastases across 11 international institutions in 4 countries with a median follow-up of 15.6 months. The rates of symptomatic RN were 9.4% and 8.2% in the concurrent and nonconcurrent groups, respectively ( P =.766). On multivariable logistic regression, V12 ≥ 10 cm 3 (odds ratio [OR]: 2.76; P =.006) and presence of BRAF mutation (OR: 2.20; P =.040) were associated with an increased risk of developing symptomatic RN; the use of concurrent over nonconcurrent therapy was not associated with an increased risk (OR: 1.06; P =.877). There were 20 grade 3 toxic events reported, and no grade 4 events reported. One patient experienced a grade 5 intracranial hemorrhage. The median overall survival was 36.1 and 19.8 months for the concurrent and nonconcurrent groups (log-rank P =.051), respectively. CONCLUSION: Concurrent administration of ICIs and SRS are not associated with an increased risk of RN. Tumors harboring BRAF mutation, or perhaps prior exposure to targeted agents, may increase this risk. Radiosurgical optimization to maintain V12 < 10 cm 3 is a potential strategy to reduce the risk of RN.